Reported 2 days ago
Amgen has reported significant findings from its Phase 3 DeLLphi-304 trial for the lung cancer drug IMDELLTRA, showing a 40% reduction in death risk and an increase in median overall survival by over 5 months for patients with small cell lung cancer. The drug, a targeted immunotherapy, effectively binds to cancer cells while sparing healthy ones. These results may lead to full FDA approval following its accelerated approval last year.
Source: YAHOO